Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetes

Alicia J. Jenkins, Andrzej S. Januszewski, Adrienne Kirby, Christel Hendrieckx, Sybil A. McAuley, Melissa H. Lee, Barbora Paldus, Sara Vogrin, Martin I. de Bock, Mary B. Abraham, Leon A. Bach, Morton G. Burt, Neale D. Cohen, Peter G. Colman, Elizabeth A. Davis, D. J. Holmes-Walker, Joey Kaye, Anthony C. Keech, Kavita Kumareswaran, Richard J. MacIsaacRoland W. McCallum, Catriona M. Sims, Jane Speight, Stephen N. Stranks, Vijaya Sundararajan, Steven Trawley, Glenn M. Ward, Timothy W. Jones, David N. O'Neal, for the Australian Juvenile Diabetes Research Fund (JDRF) Closed-Loop Research Group

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Less than 20% of Australians with type 1 diabetes (T1D) meet recommended glucose targets. Technology use is associated with better glycaemia, with the most advanced being automated insulin delivery (AID) systems, which are now recommended as gold-standard T1D care. Our Australian AID trial shows a wide spectrum of adults with T1D can achieve recommended targets. Other studies, including lived experience data, are supportive. Insulin pumps are not subsidised for most Australian adults with T1D. We advocate change.

Original languageEnglish
Number of pages6
JournalInternal Medicine Journal
DOIs
Publication statusAccepted/In press - 2024

Keywords

  • Advocacy
  • Automated insulin delivery
  • Clinical trial
  • Hybrid closed loop pump
  • Type 1 diabetes

Cite this